investors@edesabiotech.com
Condensed Interim Consolidated Statements of Operations
(Unaudited)
Three Months Ended
---------------------------------------
December 31, 2024 December 31,2023
------------------- ------------------
Expenses:
Research and development 1,019,818 704,458
General and
administrative 878,871 1,152,971
-------------- -------------
Loss from operations (1,898,689) (1,857,429)
Other Income (Loss):
Reimbursement grant
income 301,195 120,834
Other income (loss) (19,759) 58,144
-------------- -------------
Net loss (1,617,253) (1,678,451)
Exchange differences on
translation 18,656 (572)
-------------- -------------
Net comprehensive loss $ (1,598,597) $ (1,679,023)
============== =============
Weighted average number of
common shares 3,345,135 3,128,024
Loss per common share -
basic and diluted $ (0.48) $ (0.54)
-------------- -------------
Condensed Interim Consolidated Balance Sheets
(Unaudited)
December 31, 2024 September 30, 2024
------------------- --------------------
Assets:
Cash and cash equivalents $ 1,563,502 $ 1,037,320
Other current assets 508,426 638,302
Non-current assets 2,092,253 2,138,360
--------------- ----------------
Total Assets $ 4,164,181 $ 3,813,982
=============== ================
Liabilities and shareholders'
equity:
Current liabilities $ 1,900,219 $ 1,832,827
Shareholders' equity 2,263,962 1,981,155
--------------- ----------------
Total liabilities and
shareholders' equity $ 4,164,181 $ 3,813,982
=============== ================
Condensed Interim Consolidated Statements of Cash
Flows
(Unaudited)
Three Months Ended
---------------------------------------
December 31, 2024 December 31,2023
------------------- ------------------
Cash flows from operating
activities:
Net loss $ (1,617,253) $ (1,678,451)
Adjustments for non-cash
items 124,292 229,388
Change in working capital
items (24,242) 42,535
-------------- -------------
Net cash used in operating
activities (1,517,203) (1,406,528)
Net cash provided by
financing activities 2,071,545 305,742
Effect of exchange rate
changes on cash and cash
equivalents (28,160) 7,176
-------------- -------------
Net change in cash and cash
equivalents 526,182 (1,093,610)
Cash and cash equivalents,
beginning of period 1,037,320 5,361,397
-------------- -------------
Cash and cash equivalents,
end of period $ 1,563,502 $ 4,267,787
============== =============
(END) Dow Jones Newswires
February 14, 2025 16:15 ET (21:15 GMT)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.